Market Overview

Alnylam, Tekmira Resolve All Litigation; Alnylam to Make $65M One-Time Payment

Related ALNY
Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia
The Biotech Stock With The Biggest Head Of Steam
Related TKMR
Momentum Stocks Showing Weakness
Top 5 Performing Biotech Stocks Of 2014

Alnylam (NASDAQ: ALNY) and Tekmira Pharma (NASDAQ: TKMR) announced a settlement agreement that resolves all litigation between the companies, and has signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues between the companies. As a result of the restructuring and new agreements, Tekmira will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

Posted-In: News Legal


Related Articles (ALNY + TKMR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional